Optimization of Glycemic Control and Restenosis Prevention in Diabetic Patients Undergoing Percutaneous Coronary Interventions

Journal of the American College of Cardiology

Volumn 43, Issue 1, 2004, Pages 15-17

  Kornowski, Ran ^a   Fuchs, Shmuel ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ANGIOGRAPHY; DIABETES MELLITUS; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; MULTIVARIATE ANALYSIS; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; RISK ASSESSMENT;

EID: 0347052782     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.10.016     Document Type: Editorial

References (29)

1. Laskey WK, Selzer F, Vlachos HA, et al., and the Dynamic Registry Investigators. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2002;90:1062-7.
2. Marso SP, Giorgi LV, Johnson WL, et al. Diabetes mellitus is associated with a shift in the temporal risk profile of inhospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years. Am Heart J 2003;145:270-7.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
5. Ghosh J, Weiss MB, Kay RH, Frishman WH. Diabetes mellitus and coronary artery disease: therapeutic considerations. Heart Dis 2003;5:119-28.
6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
7. Stein B, Weintraub WS, Gebhart SSP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transmural coronary angioplasty. Circulation 1995;91:979-89.
8. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier J. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818-25.
9. Carrozza JP Jr., Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993;118:344-9.
10. Lau KW, Ding ZP, Johan A, Lim Y. Midterm angiographic outcome of single-vessel intracoronary stent placement in diabetic versus non-diabetic patients: a matched comparative study. Am Heart J 1998;136:150-5.
11. Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998;32:584-9.
12. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-73.
13. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular study. Circulation 1997;95:1366-9.
14. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002;40:2082-9.
15. Corpus RA, George PB, House JA, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004;43:8-14.
16. Mazeika P, Prasad N, Bui S, Seidelin PH. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 2003;145:1013-21.
17. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528-35.
18. Kornowski R, Lansky AJ. Current perspectives on interventional treatment strategies in diabetic patients with coronary artery disease. Catheter Cardiovasc Interv 2000;50:245-54.
19. Winocour PD, Richardson M, Kinglough-Rathbone RL. Continued platelet interaction with de-endothelialized aorta associated with slower re-endothelialization and more extensive intimai hyperplasia in spontaneously diabetic BB Wistar rats. Int J Exp Pathol 1993;74:603-13.
20. McClain DA, Paterson AJ, Ross MD, Wei X. Glucose and glucosamine regulate growth factors gene expression in vascular smooth muscle cells. Proc Natl Acad Sci USA 1992;89:8150-4.
21. Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose-induced expression of pro-inflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003;52:1256-64.
22. Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-30.
23. Farb A, Weber DK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002;105:2974-80.
24. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003;52:173-80.
25. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000;36:1529-35.
26. Nathan DM, Lachin J, Cleary P, et al., Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348:2294-303.
27. Cipollone F, Fazia M, Iezzi A, et al. High pre-procedural non-HDL cholesterol is associated with enhanced oxidative stress and monocyte activation after coronary angioplasty: possible implications in restenosis. Heart 2003;89:773-9.
28. Morice MC, Serruys PW, Sousa JE, et al., for the RAVEL Study Group. Randomized study with the sirolimus-coated BX velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
29. O'Neill WW, Leon MB. Drug-eluting stents: costs versus clinical benefit. Circulation 2003;107:3008-11.